89 related articles for article (PubMed ID: 2100561)
21. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head.
Liao Q; Zhao YP; Yang YC; Li LJ; Long X; Han SM
Hepatobiliary Pancreat Dis Int; 2007 Dec; 6(6):641-5. PubMed ID: 18086633
[TBL] [Abstract][Full Text] [Related]
22. Tumour markers in pancreatic cancer.
Haglund C; Kuusela P; Roberts PJ
Ann Chir Gynaecol; 1989; 78(1):41-53. PubMed ID: 2667448
[TBL] [Abstract][Full Text] [Related]
23. [Role of serum markers and or various clinical parameters in the diagnosis of pancreatic carcinoma].
Meggiato T; Basso D; Piccoli A; Del Favero G; Fogar P; Panozzo MP; Scalon P; Fabris C; Angonese C; Faggian D
Ann Ital Med Int; 1989; 4(4):367-72. PubMed ID: 2487791
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of pancreatic oncofetal antigen (POA) in the diagnosis of pancreatic cancer].
Nishida K
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt 2):601-8. PubMed ID: 6349542
[TBL] [Abstract][Full Text] [Related]
25. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
Chen SB
Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
[TBL] [Abstract][Full Text] [Related]
26. The value of combined use of serum tumour markers and nuclear magnetic spectroscopy of plasma in the detection of pancreatic cancer among patients with jaundice or cholestasis: results from a prospective study.
Pasanen PA; Kauppinen R; Eskelinen M; Partanen K; Pikkarainen P; Alhava E
Anticancer Res; 1993; 13(3):763-8. PubMed ID: 8317910
[TBL] [Abstract][Full Text] [Related]
27. Tissue polypeptide antigen, galactosyltransferase isoenzyme II and pancreatic oncofetal antigen serum determination: role in pancreatic cancer diagnosis.
Basso D; Fabris C; Panucci A; Del Favero G; Angonese C; Plebani M; Petrin P; Burlina A; Naccarato R
Int J Pancreatol; 1988; 3 Suppl 1():S95-100. PubMed ID: 3145303
[TBL] [Abstract][Full Text] [Related]
28. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E
Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of CA 19-9 serum course in pancreatic cancer.
Safi F; Schlosser W; Falkenreck S; Beger HG
Hepatogastroenterology; 1998; 45(19):253-9. PubMed ID: 9496523
[TBL] [Abstract][Full Text] [Related]
30. [Which is the best monitoring study (tumor marker, computed tomography or 18F-fluoro-2-deoxy-D-glucose positron emission tomography) to evaluate efficacy of chemotherapy on unresectable pancreatic cancer ?].
Kobayashi N; Fujita K; Fujisawa T; Takahashi H; Yoneda M; Abe Y; Inamori M; Kirikoshi H; Kubota K; Saito S; Nakajima A
Gan To Kagaku Ryoho; 2008 Jan; 35(1):65-70. PubMed ID: 18195530
[TBL] [Abstract][Full Text] [Related]
31. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer.
Ozkan H; Kaya M; Cengiz A
Hepatogastroenterology; 2003; 50(53):1669-74. PubMed ID: 14571813
[TBL] [Abstract][Full Text] [Related]
32. [Serum tumor markers at exocrine adenocarcinoma of pancreas].
Holubec L; Finek J; Topolcan O; Svobodová S
Cas Lek Cesk; 2005; 144(2):86-8; discussion 89. PubMed ID: 15807292
[TBL] [Abstract][Full Text] [Related]
33. Expression of tumor-associated carbohydrate antigens correlates with hepatic metastasis of pancreatic cancer: clinical and experimental studies.
Takamori H; Hiraoka T; Yamamoto T
Hepatogastroenterology; 1996; 43(9):748-55. PubMed ID: 8799425
[TBL] [Abstract][Full Text] [Related]
34. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
Safi F; Roscher R; Beger HG
Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
[TBL] [Abstract][Full Text] [Related]
35. Significance of RCAS1 antigen in hepatocellular, cholangiocellular and pancreatic carcinomas.
Enjoji M; Nakashima M; Yamaguchi K; Kotoh K; Nakamuta M
J Gastroenterol Hepatol; 2005 Aug; 20(8):1143-8. PubMed ID: 16048560
[TBL] [Abstract][Full Text] [Related]
36. [Tumor markers in the diagnosis and therapy of intestinal neoplasms].
Gräter H
Schweiz Rundsch Med Prax; 1992 Jul; 81(31-32):943-4. PubMed ID: 1496207
[TBL] [Abstract][Full Text] [Related]
37. [TA90--new neoplastic marker].
Rudzki S; Gołyski J; Bronikowski P; Gołyska D
Pol Merkur Lekarski; 2010 Mar; 28(165):211-3. PubMed ID: 20815170
[TBL] [Abstract][Full Text] [Related]
38. [Diagnosis of pancreatic cancer with simultaneous detection of a pancreatic-cancer-associated antigen and pancreas-specific antigen].
Zhao XY; Yu SY; Bai L
Zhonghua Nei Ke Za Zhi; 1990 Oct; 29(10):612-5, 638-9. PubMed ID: 2086001
[TBL] [Abstract][Full Text] [Related]
39. [Cancer of the pancreas and the periampullar region: usefulness of tumor markers produced with the monoclonal antibody technique].
Valenza V; Maussier ML; D'Errico G; Lemmo GF; Frontera D; Ferrante A; Saletnich I; Valli A; Quarantelli M
J Nucl Med Allied Sci; 1990; 34(4 Suppl):131-4. PubMed ID: 2092109
[No Abstract] [Full Text] [Related]
40. Identification of fucosylated haptoglobin as a novel tumor marker for pancreatic cancer and its possible application for a clinical diagnostic test.
Miyoshi E; Shinzaki S; Moriwaki K; Matsumoto H
Methods Enzymol; 2010; 478():153-64. PubMed ID: 20816478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
